Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 14 806 M
EBIT 2016 7 609 M
Net income 2016 -
Debt 2016 -
Yield 2016 -
Sales 2017 16 170 M
EBIT 2017 8 737 M
Net income 2017 215 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 8,35
P/E ratio 2017 422,59
Capi. / Sales2016 6,33x
Capi. / Sales2017 5,79x
Capitalization 93 702 M
More Financials
Company
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products.The firm offers products under the following brands: BOTOX, Juvederm, Linzess, Namenda, Restasis, Latisse, Teflaro, Lo Loestrin Fe, Bystolic, DORYX, Saphris, Fetzima, Namenda XR, Namzaric, Viberzi,... 
Sector
Pharmaceuticals
Calendar
09/08 | 04:30pmPresentation
More about the company
Surperformance© ratings of Actavis Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACTAVIS INC
08/29DJMondelez Walks Away After Hershey Spurns Raised Bid
08/24DJPfizer Buys Part of AstraZeneca's Antibiotics Business
08/09DJBotox Maker Allergan's Revenue Climbs, but Loss More Than Doubles -- WSJ
08/08DJAllergan Revenue Increases, Though Loss Widens--Update
08/08DJMARKET SNAPSHOT : Stocks Back Off All-time Highs As Health-care Stocks Slump
08/08DJMARKET SNAPSHOT : Stocks Retreat From Records As Health-care Stocks Slump
08/08DJU.S. Stocks Slip Despite Surge in Energy Sector
08/05DJPFIZER : Business Groups Sue Over Inversion Rules -- WSJ
08/04DJPFIZER : Business Groups Sue U.S. Government Over Tax-Inversion Rules -- 2nd Upd..
08/04 Business groups sue over new U.S. limit on tax-driven foreign buyouts
More news
Sector news : Pharmaceuticals - NEC
06:16pDJAgrium, Potash Report Merger Talks
04:01pDJOrexigen in Canadian Marketing Pact With Valeant for Diet Drug
08:49aDJBusiness Watch -- WSJ
08/29 Mylan to launch generic EpiPen at half the price of original
08/29DJMondelez Walks Away After Hershey Spurns Raised Bid
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 299 $
Spread / Average Target 26%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Brenton L. Saunders President, Chief Executive Officer & Director
Paul M. Bisaro Executive Chairman
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACTAVIS INC93 702
JOHNSON & JOHNSON16.74%328 086
PFIZER INC.8.77%212 965
ROCHE HOLDING LTD.-12.84%212 954
NOVARTIS AG-10.83%208 887
MERCK & CO., INC.19.29%174 236
More Results